Bandaram Pharma Packtech Ltd (524602)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Bandaram Pharma's revenue was ₹24.0 Cr (+195.7% year on year, -8.8% on the previous quarter), and net profit ₹0.7 Cr; the operating margin was 6.4%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹24.0 | +195.7% | -8.8% |
| Operating profit | ₹1.5 | +145.2% | +88.4% |
| Net profit | ₹0.7 | — | +660.4% |
| EPS (₹) | 0.11 | +450.0% | +120.0% |
| Operating margin | 6.4% | — | — |
📢 Recent Corporate Announcements
Bandaram Pharma Packtech has scheduled a board meeting for September 30, 2026, to consider a proposed scheme of arrangement or amalgamation. The micro-cap healthcare service provider currently has a market capitalization of Rs 83 Cr and generated TTM revenue of Rs 79 Cr. In line with insider trading regulations, the trading window for dealing in company securities is closed from September 27, 2026, until 48 hours post-declaration of the outcome. Details regarding the merging entities, swap ratio, and deal size have not yet been disclosed.
- Board meeting scheduled for September 30, 2026, to evaluate a Scheme of Arrangement/Amalgamation
- Trading window closed starting September 27, 2026, reopening 48 hours after board decision
- Target or merging entities and financial terms are currently not disclosed
- Company trades at Rs 20.2 with an Rs 83 Cr market capitalization as of the announcement
Bandaram Pharma Packtech reported a strong consolidated performance for Q1 FY27, with revenue jumping to ₹23.95 Cr from ₹8.10 Cr in the same quarter last year. Consolidated net profit rose significantly to ₹0.68 Cr compared to a marginal ₹0.02 Cr YoY. This growth is primarily driven by its 55% subsidiary, VSR Paper and Packaging Limited, which contributed ₹22.42 Cr to the top line. However, the standalone pharma business remains under pressure, reporting a net loss of ₹0.35 Cr on revenue of ₹2.98 Cr.
- Consolidated revenue for Q1 FY27 reached ₹23.95 Cr, a 195% increase over Q1 FY26 (₹8.10 Cr).
- Consolidated PAT grew to ₹68.44 lakhs from ₹2.47 lakhs in the year-ago period.
- Subsidiary VSR Paper and Packaging Limited (55% stake) contributed ₹22.42 Cr in revenue and ₹1.01 Cr in profit.
- Standalone operations reported a net loss of ₹35.68 lakhs despite revenue growing to ₹2.98 Cr from ₹0.75 Cr YoY.
- Board approved re-appointment of Independent Director Suryaprakasa Rao Bommisetti for a 5-year term starting March 2027.
Bandaram Pharma Packtech reported a significant turnaround in consolidated performance for Q1 FY27, with revenue reaching ₹23.95 Cr, a 195% increase compared to ₹8.10 Cr in Q1 FY26. Consolidated Net Profit rose to ₹0.68 Cr from just ₹0.02 Cr in the year-ago period. However, the standalone business remains under pressure, reporting a loss of ₹0.36 Cr on revenue of ₹2.98 Cr. The overall growth is heavily reliant on its 55% subsidiary, VSR Paper and Packaging Limited, which contributes the majority of the group's top and bottom lines.
- Consolidated Revenue from operations grew 195% YoY to ₹23.95 Cr
- Consolidated Net Profit increased to ₹68.44 lakhs compared to ₹2.47 lakhs in Q1 FY26
- Standalone operations reported a net loss of ₹35.68 lakhs for the quarter
- Consolidated EPS improved to ₹0.11 from ₹0.02 YoY
- VSR Paper and Packaging Limited (55% subsidiary) remains the primary revenue driver
Bandaram Pharma Packtech has scheduled a board meeting for August 13, 2026, to approve un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company enters this reporting period with a TTM revenue of ₹63 Cr but a low operating margin of 4.6%. Net profit for FY26 stood at ₹0.45 Cr, a significant drop from ₹0.99 Cr in FY25. Investors will be monitoring for any recovery in profitability given the high P/E ratio of 99.1.
- Board meeting scheduled for August 13, 2026, to consider Q1 FY27 results.
- Trading window for insiders has been closed since July 1, 2026.
- Company reported a TTM revenue of ₹63 Cr against a market capitalization of ₹52 Cr.
- Operating profit margin remains thin at 4.6% as per latest TTM data.
- Promoter holding has decreased from 75.0% in September 2025 to 62.66% in March 2026.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
